Literature DB >> 1891079

The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions.

J A Burnham1, R R Wright, J Dreisbach, R S Murray.   

Abstract

Gadolinium (Gd) enhancement of brain lesions by MRI is a marker of active blood-brain barrier damage secondary to an inflammatory process. We studied the effects of high-dose (1,000 mg/d) intravenous (IV) methylprednisolone (Mp) for 4 to 8 days on Gd-enhancing lesions in seven patients with acute demyelinating diseases and compared pretreatment brain MRIs with studies obtained 1 to 4 days after treatment. Five patients had complete suppression, and two had significant suppression of Gd enhancement following treatment. In addition, six of seven patients had Gd-enhancing lesions that explained their clinical signs; in five of six of these patients, suppression of the Gd-enhanced lesions temporally correlated with clinical improvement. Thus, short courses of high-dose IV Mp suppress Gd enhancement in acute demyelinating lesions, and this correlates with clinical improvement.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891079     DOI: 10.1212/wnl.41.9.1349

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  MRI of the facial nerve in idiopathic facial palsy.

Authors:  I Saatçi; F Sahintürk; L Sennaroğlu; F Boyvat; B Gürsel; A Besim
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

2.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

3.  Sensitivity of orbital magnetic resonance imaging in acute demyelinating optic neuritis.

Authors:  Lulu L C D Bursztyn; Lindsey B De Lott; Myria Petrou; Wayne T Cornblath
Journal:  Can J Ophthalmol       Date:  2018-08-24       Impact factor: 1.882

4.  Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.

Authors:  E M Martínez-Cáceres; M A Barrau; L Brieva; C Espejo; N Barberà; X Montalban
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

5.  Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system.

Authors:  Carola Förster; Christine Silwedel; Nikola Golenhofen; Malgorzata Burek; Silke Kietz; Joachim Mankertz; Detlev Drenckhahn
Journal:  J Physiol       Date:  2005-03-24       Impact factor: 5.182

6.  MRI in acute disseminated encephalomyelitis.

Authors:  K S Caldemeyer; R R Smith; T M Harris; M K Edwards
Journal:  Neuroradiology       Date:  1994-04       Impact factor: 2.804

7.  Database for serial magnetic resonance imaging in multiple sclerosis.

Authors:  F Barkhof; A J Thompson; L Kappos; J J Nauta; T Yousri; I Berry; G Scotti; B Appel; P S Tofts; D H Miller
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

8.  Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone.

Authors:  S T Frequin; R A Wevers; M Braam; F Barkhof; O R Hommes
Journal:  J Neurol       Date:  1993-05       Impact factor: 4.849

9.  Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis.

Authors:  L Claudio; C S Raine; C F Brosnan
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  The effect of methylprednisolone on monocyte eicosanoid production in patients with multiple sclerosis.

Authors:  P F Kirk; J D Williams; M M Petersen; D A Compston
Journal:  J Neurol       Date:  1994-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.